Applies to PALOMA-2: postmenopausal women with ER-positive, HER2-negative advanced breast cancer and no prior systemic treatment for advanced disease (IBRANCE plus letrozole vs placebo plus letrozole)
Applies to PALOMA-3: women with HR-positive, HER2-negative advanced breast cancer whose disease progressed on or after prior endocrine therapy (IBRANCE plus fulvestrant vs placebo plus fulvestrant)
How long does Ibrance plus letrozole delay progression vs letrozole alone (PALOMA-2)?
Applies to PALOMA-2: postmenopausal women with ER-positive, HER2-negative advanced breast cancer and no prior systemic treatment for advanced disease (IBRANCE plus letrozole vs placebo plus letrozole)
Note: Table 12 columns are IBRANCE plus letrozole and placebo plus letrozole, in that order.
Does Ibrance plus letrozole help patients live longer (PALOMA-2 overall survival)?
Applies to PALOMA-2: postmenopausal women with ER-positive, HER2-negative advanced breast cancer and no prior systemic treatment for advanced disease (IBRANCE plus letrozole vs placebo plus letrozole)
What was the response rate with Ibrance plus letrozole (PALOMA-2)?
Applies to PALOMA-2: postmenopausal women with ER-positive, HER2-negative advanced breast cancer and no prior systemic treatment for advanced disease (IBRANCE plus letrozole vs placebo plus letrozole)
How long does Ibrance plus fulvestrant delay progression vs fulvestrant alone (PALOMA-3)?
Applies to PALOMA-3: women with HR-positive, HER2-negative advanced breast cancer whose disease progressed on or after prior endocrine therapy (IBRANCE plus fulvestrant vs placebo plus fulvestrant)
Note: Table 13 columns are IBRANCE plus fulvestrant and placebo plus fulvestrant, in that order.
Does Ibrance plus fulvestrant help patients live longer (PALOMA-3 overall survival)?
Applies to PALOMA-3: women with HR-positive, HER2-negative advanced breast cancer whose disease progressed on or after prior endocrine therapy (IBRANCE plus fulvestrant vs placebo plus fulvestrant)
What was the response rate with Ibrance plus fulvestrant (PALOMA-3)?
Applies to PALOMA-3: women with HR-positive, HER2-negative advanced breast cancer whose disease progressed on or after prior endocrine therapy (IBRANCE plus fulvestrant vs placebo plus fulvestrant)
Were Ibrance plus letrozole results consistent across subgroups (PALOMA-2)?
Applies to PALOMA-2: postmenopausal women with ER-positive, HER2-negative advanced breast cancer and no prior systemic treatment for advanced disease (IBRANCE plus letrozole vs placebo plus letrozole)
Were Ibrance plus fulvestrant results consistent across subgroups (PALOMA-3)?
Applies to PALOMA-3: women with HR-positive, HER2-negative advanced breast cancer whose disease progressed on or after prior endocrine therapy (IBRANCE plus fulvestrant vs placebo plus fulvestrant)
What are the long-term side effects of Ibrance plus letrozole (PALOMA-2)?
Applies to PALOMA-2: postmenopausal women with ER-positive, HER2-negative advanced breast cancer and no prior systemic treatment for advanced disease (IBRANCE plus letrozole vs placebo plus letrozole)
What are the long-term side effects of Ibrance plus fulvestrant (PALOMA-3)?
Applies to PALOMA-3: women with HR-positive, HER2-negative advanced breast cancer whose disease progressed on or after prior endocrine therapy (IBRANCE plus fulvestrant vs placebo plus fulvestrant)